Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder

References

• Norton P, Brubaker L. Urinary incontinence in women. Lancet 2006;367:57–67
   PubMed Web of Science ®Google Scholar
• McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001;7:S62–75
   PubMed Web of Science ®Google Scholar
• Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;20:CD005429
   Google Scholar
• Epstein LB, Goldberg RP. The overactive bladder and quality of life. Int J Fertil Womens Med 2005;50:30–6
   PubMed Web of Science ®Google Scholar
• Davila GW, Neimark M. The overactive bladder: prevalence and effects on quality of life. Clin Obstet Gynecol 2002;45:173–81
   PubMed Web of Science ®Google Scholar
• Bradway C. UI among older women: measurement of the effect on health-related quality of life. J Gerontol Nurs 2003;29:13–9
   PubMedGoogle Scholar
• Hampel C, Artibani W, Espuna Pons M, Haab F, et al. Understanding the burden of stress UI in Europe: a qualitative review of the literature. Eur Urol 2004;46:15–27
   PubMed Web of Science ®Google Scholar
• Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics 1996;9:11–23
   PubMed Web of Science ®Google Scholar
• Criner JA. UI in a vulnerable population: older women. Semin Perioper Nurs 2001;10:33–7
   PubMedGoogle Scholar
• Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. Value Health 2006;9:272–4
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther 1999;21:634–42
   PubMed Web of Science ®Google Scholar
• Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000;16:149–55
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, et al.; Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414–21
   Google Scholar
• Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001;18:277–304
   PubMed Web of Science ®Google Scholar
• Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006;68:38–48
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology 2000;56:41–9
   PubMed Web of Science ®Google Scholar
• Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006;68:3–8
   PubMed Web of Science ®Google Scholar
• Brubaker L, Chapple C. Introduction. Urology 2006;68:1–2
   Web of Science ®Google Scholar
• Office of New Drugs and Office of Medical Policy: guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD: Center for Drug Evaluation and Research (CDER), 2006
   Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74
   Google Scholar
• Ware JE, Kosinski M, Dewey JE, Gandek B. A manual for users of the SF-8 Health Survey. Lincoln, RI: QualityMetric Incorporated, 2001
   Google Scholar
• Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006;68:29–37
   Google Scholar
• Hajjar RR. Psychosocial impact of UI in the elderly population. Clin Geriatr Med 2004;20:553–64, viii
   Google Scholar
• Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17–28
   PubMed Web of Science ®Google Scholar
• Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004;13:115–38
   PubMed Web of Science ®Google Scholar
• Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed UI. BJU Int 2003;92:731–5
   PubMed Web of Science ®Google Scholar
• Minassian VA, Drutz HP, Al-Badr A. UI as a worldwide problem. Int J Gynaecol Obstet 2003;82:327–38
   PubMed Web of Science ®Google Scholar
• Best SJ, Krueger B, Hubbard C, Smith A. An assessment of the generalizability of internet surveys. Soc Sci Comput Rev 2001;19:131–45
   Web of Science ®Google Scholar
• Wyatt, JC. When to use web-based surveys. J Am Med Inform Assoc 2000;7:426–30
   PubMed Web of Science ®Google Scholar
• Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004;4:204–15
   Google Scholar
• Umlauf MG, Goode S, Burgio KL. Psychosocial issues in geriatric urology: problems in treatment and treatment seeking. Urol Clin North Am 1996;23:127–36
   Google Scholar